Abstract
Liquid biopsy to provide a mutational snapshot of diffuse large B-cell lymphoma is an emerging technology of exciting potential utility. The report by Alcoceba et al. assesses the tractability of the EuroClonality-NDC assay to profile lymphoma using cell-free DNA and highlights the prognostic implication of attaining a major molecular response to therapy. Commentary on: Alcoceba et al. Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19458.
Original language | English |
---|---|
Number of pages | 2 |
Journal | British Journal of Haematology |
DOIs |
|
Publication status | Accepted/In press - 30 May 2024 |
Keywords
- diffuse large B cell lymphoma
- EuroClonality NGS DNA Capture
- liquid biopsy